Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by AbbVie Inc

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OnabotulinumtoxinA

            Therapeutic Area: Neurology Product Name: Botox

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 15, 2021

            Details:

            Allergan Aesthetics and Allergan will present results from 16 abstracts spanning pre-clinical and clinical studies evaluating key safety and efficacy of BOTOX® (onabotulinumtoxinA) across multiple therapeutic and cosmetic indications.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Epcoritamab

            Therapeutic Area: Oncology Product Name: GEN3013

            Highest Development Status: Phase III Product Type: Large molecule

            Recipient: Genmab

            Deal Size: $3,150.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration January 13, 2021

            Details:

            A USD 40 million milestone payment was triggered by the first patient dosed in the Phase 3 study of subcutaneous epcoritamab versus investigator’s choice of chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): DF1001,Pembrolizumab

            Therapeutic Area: Oncology Product Name: DF1001

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Recipient: Dragonfly Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 12, 2021

            Details:

            The opt-in grants AbbVie exclusive worldwide intellectual property rights to develop and commercialize products directed to this first specific target, developed using Dragonfly's TriNKET™ technology platform.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Risankizumab

            Therapeutic Area: Gastroenterology Product Name: Skyrizi

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Pennsylvania University

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 07, 2021

            Details:

            A significantly greater proportion of patients with Crohn's disease treated with either dose of risankizumab achieved both primary endpoints, demonstrating statistically significant results for clinical remission and endoscopic response at week 12 compared to placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Risankizumab

            Therapeutic Area: Immunology Product Name: Skyrizi

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 05, 2021

            Details:

            In KEEPsAKE-1 and KEEPsAKE-2, 57 and 51 percent of patients receiving risankizumab achieved the primary endpoint of ACR20 response at week 24, respectively, versus 34 and 27 percent receiving placebo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ibrutinib,Rituximab

            Therapeutic Area: Oncology Product Name: Imbruvica

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 23, 2020

            Details:

            Updates are based on more than five years of Phase 3 iNNOVATE final analysis data, which demonstrated IMBRUVICA plus rituximab significantly prolonged progression-free survival (PFS) versus rituximab alone in adults with WM.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ABBV-47D11

            Therapeutic Area: Infections and Infectious Diseases Product Name: ABBV-47D11

            Highest Development Status: Phase I Product Type: Large molecule

            Recipient: Harbour BioMed

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration December 15, 2020

            Details:

            The fully human H2L2 transgenic Harbour Mice® platform enabled the quick discovery and development of several potent candidates of which ABBV-47D11’s cross-reactive neutralizing nature made it a compelling candidate to take it into development.